About / News

October 21, 2008

CUBICIN® Outcomes Registry and Experience (CORE®) marks milestone -- Five Years and 5,000 Patient Entries Later

more

October 16, 2008

Cubist Pharmaceuticals Q3 2008 Revenues Up 41%; Net Income Up 39%: Total Revenues $112.4 Million; CUBICIN® Net Product Revenues $110.6 Million

GAAP Basic and Diluted Net Income of $0.49 and $0.44 Per Share, Respectively NON-GAAP Basic and Diluted Net Income of $0.54 and $0.48 Per Share, Respectively

Earnings Conference Call & Webcast Today (With Slides) at 5:00 p.m. EDT more

September 30, 2008

Cubist Opens New Research Facility at Lexington Headquarters

more

September 8, 2008

Cubist Provides Update on Advancing Product Pipeline

more

July 2, 2008

Cubist to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.

- Leverages Proven U.S. Acute Care Sales Organization
- Complements Cubist's Gram-Positive CUBICIN more

June 24, 2008

Cubist Testifies on Need to Encourage Antibiotic Research and Development

Antimicrobial Resistance Reaching "Crisis Point" more

June 24, 2008

Cubist Appoints Mark H.N. Corrigan, M.D., to its Board of Directors

more

June 16, 2008

Cubist Appoints Nancy J. Hutson, Ph.D., to its Board of Directors

more

April 24, 2008

Dyax & Cubist Sign Development and Commercialization Agreement for DX-88 Surgical Indications

more

February 12, 2008

Cubist Names Steven C. Gilman, Ph.D., as SVP, Discovery and Non-Clinical and CSO

more

August 17, 2006

NEJM Publishes results of Cubist's Landmark Study of S. aureus Blood Stream Infections

more

May 25, 2006

FDA Approves Expanded Label for IV Antibiotic CUBICIN®

Click here for expanded Label

more